New challenges in the use of nanomedicine in cancer therapy
- PMID: 34856849
- PMCID: PMC8805951
- DOI: 10.1080/21655979.2021.2012907
New challenges in the use of nanomedicine in cancer therapy
Abstract
Nanomedicines are applied as alternative treatments for anticancer agents. For the treatment of cancer, due to the small size in nanometers (nm), specific site targeting can be achieved with the use of nanomedicines, increasing their bioavailability and conferring fewer toxic side effects. Additionally, the use of minute amounts of drugs can lead to cost savings. In addition, nanotechnology is effectively applied in the preparation of such drugs as they are in nm sizes, considered one of the earliest cutoff values for the production of products utilized in nanotechnology. Early concepts described gold nanoshells as one of the successful therapies for cancer and associated diseases where the benefits of nanomedicine include effective active or passive targeting. Common medicines are degraded at a higher rate, whereas the degradation of macromolecules is time-consuming. All of the discussed properties are responsible for executing the physiological behaviors occurring at the following scale, depending on the geometry. Finally, large nanomaterials based on organic, lipid, inorganic, protein, and synthetic polymers have also been utilized to develop novel cancer cures.
Keywords: Nanomedicine; active targeting; nanomaterials; nanoshells; passive targeting.
Conflict of interest statement
No potential conflict of interest was reported by the author(s).
Similar articles
-
Nanosize drug delivery system.Curr Pharm Biotechnol. 2013;14(15):1221. doi: 10.2174/138920101415140804121008. Curr Pharm Biotechnol. 2013. PMID: 25106648
-
Nano based drug delivery systems: recent developments and future prospects.J Nanobiotechnology. 2018 Sep 19;16(1):71. doi: 10.1186/s12951-018-0392-8. J Nanobiotechnology. 2018. PMID: 30231877 Free PMC article. Review.
-
Oral Nanomedicine: Challenges and Opportunities.Adv Mater. 2024 Feb;36(6):e2306081. doi: 10.1002/adma.202306081. Epub 2023 Nov 30. Adv Mater. 2024. PMID: 37724825 Review.
-
Selected nanotechnologies and nanostructures for drug delivery, nanomedicine and cure.Bioprocess Biosyst Eng. 2020 Aug;43(8):1339-1357. doi: 10.1007/s00449-020-02330-8. Epub 2020 Mar 19. Bioprocess Biosyst Eng. 2020. PMID: 32193755 Review.
-
Artificial intelligence aids in development of nanomedicines for cancer management.Semin Cancer Biol. 2023 Feb;89:61-75. doi: 10.1016/j.semcancer.2023.01.005. Epub 2023 Jan 20. Semin Cancer Biol. 2023. PMID: 36682438 Review.
Cited by
-
Modular and efficient synthesis of a poly (propylene imine) (PPI) dendron applied to acid-sensitive doxorubicin conjugation.Tetrahedron. 2022 Oct 22;125:133044. doi: 10.1016/j.tet.2022.133044. Epub 2022 Sep 21. Tetrahedron. 2022. PMID: 36338452 Free PMC article.
-
Myocardial Cell Preservation from Potential Cardiotoxic Drugs: The Role of Nanotechnologies.Pharmaceutics. 2022 Dec 27;15(1):87. doi: 10.3390/pharmaceutics15010087. Pharmaceutics. 2022. PMID: 36678717 Free PMC article. Review.
-
Enhanced drug delivery with nanocarriers: a comprehensive review of recent advances in breast cancer detection and treatment.Discov Nano. 2024 Sep 7;19(1):143. doi: 10.1186/s11671-024-04086-6. Discov Nano. 2024. PMID: 39243326 Free PMC article. Review.
-
Integrating alternative therapies in overcoming chemotherapy resistance in tumors.Mol Biol Rep. 2025 Feb 17;52(1):239. doi: 10.1007/s11033-025-10361-1. Mol Biol Rep. 2025. PMID: 39961936 Review.
-
Nanosystems for chemodynamic based combination therapy: Strategies and recent advances.Front Pharmacol. 2022 Oct 28;13:1065438. doi: 10.3389/fphar.2022.1065438. eCollection 2022. Front Pharmacol. 2022. PMID: 36386143 Free PMC article. Review.
References
-
- Kola I, Landis J.. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov. 2004;3(8):711–716. - PubMed
-
- Krown SE, Northfelt DW, Osoba D, et al. Use of liposomal anthracyclines in Kaposi’s sarcoma. Seminars in oncology: Elsevier. 2004;31:36–52. - PubMed
-
- Gabizon A, Isacson R, Rosengarten O, et al. An open-label study to evaluate dose and cycle dependence of the pharmacokinetics of pegylated liposomal doxorubicin. Cancer Chemother Pharmacol. 2008;61(4):695–702. - PubMed
-
- Moghimi SM, Hunter AC, Murray JC. Nanomedicine: current status and future prospects. FASEB J. 2005;19(3):311–330. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical